Presentation: Enabling Scalable Cell Engineering Using the MaxCyte ExPERT Electroporation Platform

This content was presented at ABRF – Association of Biomolecular Resource Facilities March, 2022.

Learning Objectives:

High-performance engine accelerating the clinical translation of next generation cell therapies
  • Twenty years of experience in primary cell transfection, protein production, and genome engineering
  • Continued expansion of cell therapy partnerships with leading industry innovators and multiple programs currently in clinical trials
  • Trusted by the top academic, translational and commercial groups for their R&D, PD and MFG work

Watch Presentation

2022 ABFR presentation slide

Download slides

2022 ABFR presentation slide


Andrew Mancini

Andrew Mancini, Ph.D.

Field Application Scientist

Andrew Mancini is a Field Application Scientist at MaxCyte specializing in Cell and Gene Therapy. As a field-based scientist, Andrew works closely with MaxCyte’s partners around the world to develop novel cell engineering workflows for the development of cellular therapeutics. Prior to his time at MaxCyte, Andrew completed his PhD in Biomedical Sciences at the University of California, San Francisco and completed his postdoctoral training at Genentech in Molecular Oncology. He has broad range of experience and expertise that encompasses non-viral and viral engineering of primary immune cells, stem cells, and cell lines at both research and manufacturing scales.